Fasting Clinical Trial
Official title:
A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Lisinopril Tablets 40 mg With Zestril® (Lisinopril) 40 mg Tablets in Normal, Healthy, Adult, Male and Female Human Subjects Under Fasting Conditions.
This is a randomized, balanced, open Label, two-treatment, two-period, two-sequence, single dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in normal, healthy, adult, male and female human subjects.
Status | Completed |
Enrollment | 40 |
Est. completion date | August 2012 |
Est. primary completion date | August 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Male and non pregnant female human subjects, age in the range of 18 - 45 years. 2. Body weight within ± 15% of ideal weight as related to height and body frame according to Life Insurance Corporation (LIC) Chart. 3. Subjects with normal findings as determined by baseline history, physical examination and vital sign examination (blood pressure, pulse rate, respiration rate and axillary temperature). 4. Subjects with clinically acceptable findings as determined by haemogram, biochemistry, urinalysis and 12 lead ECG. 5. Willingness to follow the protocol requirements especially abstaining from xanthine containing food or beverages (chocolates, tea, coffee or cola drinks) or grapefruit juice, any alcoholic products, the use of cigarettes and tobacco products for 48 hours prior to dosing until after the last blood sample collection in each study period and adherence to food, fluid and posture restrictions. 6. No history of significant alcoholism. 7. No history of drug abuse (benzodiazepines and barbiturates) for the last one month and other illegal drugs for the last 6 months. 8. Non-smokers were included. Exclusion Criteria: 1. Known history of hypersensitivity to Lisinopril or related drugs. 2. Requiring medication for any ailment having enzyme-modifying activity in the previous 28 days, prior to dosing day. 3. Subjects who have taken prescription medications or over-the-counter products (including vitamins and minerals) within 14 days prior to administration of Investigational Product. 4. Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc. 5. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, haematological, gastrointestinal, endocrine, immunological or psychiatric diseases. 6. Participation in a clinical drug study or bioequivalence study 90 days prior to present study. 7. History of malignancy or other serious diseases. 8. Blood donation 90 days prior to the commencement of the study. 9. Subjects with positive HIV tests, HBsAg or Hepatitis-C tests. 10. Found positive in breath alcohol test. 11. Found positive in urine test for drug abuse. 12. History of problem in swallowing. 13. Any contraindication to blood sampling. 14. Found positive serum Beta- hCG (Human Chorionic Gonadotropin) test. 15. Lactating women (currently breast feeding). 16. Female subjects not confirming to using birth control measures, from the date of screening until the completion of the study. Abstinence, barrier methods (condom, diaphragm, etc.) were acceptable. Use of hormonal contraceptives either oral or implants. 17. Female subjects whose menstruation cycle coincided with the study periods. |
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
India | Accutest Research Lab (I) Pvt. Ltd. | Navi-Mumbai | Maharashtra |
Lead Sponsor | Collaborator |
---|---|
IPCA Laboratories Ltd. |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cmax | Sampling Hours: Pre-dose and at 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 6.25, 6.50, 6.75, 7.00, 7.25, 7.50, 7.75, 8.00, 8.50, 9.00, 10.00, 12.00, 16.00, 24.00, 48.00 and 72.00 hours post dose | 2 months | No |
Primary | AUC | Sampling Hours: Pre-dose and at 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 6.25, 6.50, 6.75, 7.00, 7.25, 7.50, 7.75, 8.00, 8.50, 9.00, 10.00, 12.00, 16.00, 24.00, 48.00 and 72.00 hours post dose | 2 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03754920 -
Prolonged Fasting With Meditation and Mild Physical Exercise
|
N/A | |
Completed |
NCT05272332 -
Gastric Ultrasound Prior to Extubation
|
||
Completed |
NCT04247464 -
Short-term Fasting as an Enhancer of Chemotherapy: Pilot Clinical Study on Colorectal Carcinoma Patients
|
N/A | |
Completed |
NCT01067001 -
Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study
|
N/A | |
Completed |
NCT00757094 -
Safety and Feasibility of Fasting While Receiving Chemotherapy
|
N/A | |
Completed |
NCT01506713 -
Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT04514380 -
Effect of Drinking Carbohydrate-containing Fluids on Gastric Residual Volume in Elderly Patients
|
||
Completed |
NCT05756868 -
The Effect of Time-Restricted Feeding on Anthropometry, Biochemical Parameters, Diet Quality and Eating Behavior
|
N/A | |
Completed |
NCT05134207 -
The Effect of Oral Carbohydrate Solution on Anxiety and Comfort in Patients Undergoing Hip Arthroplasty
|
N/A | |
Completed |
NCT05031598 -
Long-term Fasting: Multi-system Adaptations in Humans
|
N/A | |
Recruiting |
NCT04501393 -
Recommended Clear Fluid Intake Volume at 2 Hours Prior to Esophagogastroduodenoscopy for Adult Patients
|
N/A | |
Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A | |
Completed |
NCT05219136 -
Improve the Comfort, Safety and Quality of Upper Endoscopy by a Modified Fasting Protocol
|
N/A | |
Recruiting |
NCT04625608 -
Effect of Premedicant Oral Paracetamol on Gastric Volume and pH
|
Phase 4 | |
Not yet recruiting |
NCT02562638 -
Pre-Procedural Fasting in Cardiac Intervention
|
N/A | |
Completed |
NCT01954836 -
Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial
|
N/A | |
Completed |
NCT01949987 -
Does Oral Intake Decreases Postoperative Pain Score in Children
|
N/A | |
Completed |
NCT01721187 -
Satiety Effects on the Neural Valuation of Food
|
N/A | |
Completed |
NCT01713647 -
Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions
|
Phase 1 | |
Completed |
NCT01746719 -
Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition
|
Phase 1 |